Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenoviridae Infections × Tumor Necrosis Factor-alpha × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 3 HIV Infections 2 Carcinoma, Hepatocellular 2 Acquired Immunodeficiency Syndrome 2 Stomach Ulcer 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Sarcoma, Kaposi 1 Sarcoma 1 Neoplasms 1 Muscle Neoplasms 1 Hepatitis B 1 Duodenal Ulcer 1 Adenoviridae Infections 1 AIDS-Related Complex 1

Interventions

Gemcitabine 2 Cell Count 2 valrubicin 1 tretazicar 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 enadenotucirev 1 atezolizumab 1 Vaccines 1 Tumor Necrosis Factor-alpha 1 Radiotherapy 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Genetic Engineering 1 Endostatins 1 Capecitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04695327 2026-03-06

TUNIMO

TILT Biotherapeutics Ltd.

Phase 1 Completed

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡